Please note: This is a NFA-VPS product, please fill in your pet details at checkout so our Veterinary Medicines manager can approve use and avoid the order being delayed. Please click here for the Veterinary Medicines Directorate for further information on this product.
Pale red liquid for oral administration to dogs (puppies and young dogs up to one year of age).
For the treatment of roundworm infections in puppies and young dogs up to one year of age caused by:
Ascarids : Toxocara canis
Hookworms : Uncinaria stenocephala, Ancylostoma caninum
Whipworms : Trichuris vulpis
In this fixed combination product, the pyrantel and febantel act against nematodes (ascarids, hookworms and whipworms) of dogs. In particular, the spectrum of activity covers Toxocara canis, Ancyclostoma caninum and Trichuris vulpis. Its mode of action is to induce spastic paralysis and thereby allowing removal from the gastro-intestinal (GI) system by paralysis. The parasite dies upon exhaustion of its energy reserves, which occurs 2-3 days later.
Do not use simultaneously with piperazine compounds.
Parasite resistance to any particular class of anthelmintic may develop following frequent repeated use of an anthelmintic of that class.
The safety of the product has not been assessed in puppies younger than 2 weeks and weighing less than 0.600 kg.
Do not use in pregnant and lactating bitches.
In the interests of good hygiene, persons administering the drops should wash their hands afterwards.
Avoid direct contact with the skin and eyes. In case of accidental spillage wash the affected area immediately with clean running water.
For a single oral adminstration 15 mg/kg bodyweight febantel and 5 mg/kg bodyweight pyrantel (as embonate) corresponding to 14.4 mg/kg pyrantel embonate, equivalent to 1 ml/kg bodyweight.
Through intrauterine and trans-mammary infection, ascarid infestation may occur in dogs at a very early age. For some animals, especially in case of severe infections, elimination of ascarids may be incomplete, and a potential risk of infections to humans cannot be excluded. Where epidemiologically appropriate, it is recommended that treatment should be started at 2 weeks of age and should be performed repeatedly at suitable intervals (for example every 2 weeks), until weaning. Otherwise treatment should be based upon confirmed infection, for example the results of faecal examinations.
Oral administration. The product may be given directly to the animal or mixed with feed. No special dietary measures are necessary.
Mix the product by inversion of the container before drawing the required dose.
Shelf-life after first opening the immediate packaging is 12 weeks.
Do not store above 25°C.
Any unused veterinary medicinal products or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements.